


Breast Cancer Update on Targeted Therapy



CME Instructions

1. Review the activity learning objectives stated on the front cover.
2. Read the articles, including the tables and illustrative materials.
3. Proceed to the CME Registration Form. Type or print your name, address and date of birth in the spaces provided.
4. Answer each test question by circling the letter corresponding to the correct answer. Be sure to retain a copy of your answers for your records.
5. Complete the evaluation portion of the CME Registration Form. CME Registration Forms will be returned to you if the evaluation is not completed.
6. CME Registration Forms will not be accepted after the expiration date. Return the CME Registration Form before the test expires to:
Vindico Medical Education
PO Box 36
Thorofare, NJ 08086

CME Test

1. Which of the following is an example of a 21-gene signature assay that has been used successfully to identify markers predictive of treatment response.
 - a. MammaPrint
 - b. Veridex/Rotterdam
 - c. Oncotype DX
 - d. Adjuvant
 - e. None of the above
2. In a case study of biomarker discovery, Puztai and colleagues found the likelihood of gene expression profiling conducted in the context of a single phase 2 clinical trial to detect HER-2 mRNA overexpression as a single gene predictor of response to trastuzumab was _____.
 - a. High
 - b. Moderate
 - c. Low
 - d. Non-existent
3. _____ is a randomized study designed to compare the ability of the MammaPrint 70-gene signature profile versus a clinical and pathologic predictor set to identify low risk of relapse in node-negative breast cancer patients.
 - a. TAILORx
 - b. MINDACT
 - c. Oncotype DX
 - d. ATAC
 - e. None of the above
4. The first tyrosine kinase inhibitor approved for cancer treatment was _____.
 - a. Dasatinib
 - b. Sunitinib
 - c. Trastuzumab
 - d. Lapatinib
 - e. None of the above
5. Which of the following tyrosine kinase inhibitors has been approved for the treatment of HER2-positive breast cancer?
 - a. Dasatinib
 - b. Imatinib
 - c. Lapatinib
 - d. Sunitinib
 - e. None of the above
6. Which of the following tyrosine kinase inhibitors demonstrated clinical activity against HER2-positive cancers that progressed on trastuzumab?
 - a. Imatinib
 - b. Dasatinib
 - c. Sunitinib
 - d. Bevacizumab
 - e. None of the above
7. _____ is an antibody-drug conjugate currently under development for the treatment of HER2-positive breast cancer.
 - a. trastuzumab-DM1
 - b. Bevacizumab-DM1
 - c. Rituximab-DM1
 - d. Infliximab-DM1
 - e. None of the above
8. A study by Kreike and colleagues that evaluated the gene expression profile and histopathology of triple-negative breast cancer tumors found:
 - a. Low basal cluster expression
 - b. Large amount of lymphocytic infiltrate was associated with survival free of distant metastasis
 - c. Presence of central fibrosis was associated with survival free of distant metastasis
 - d. All of the above
 - e. None of the above-

CME Registration Form

APRIL 25, 2008
 Breast Cancer Update on Targeted Therapy

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15

Time spent on this activity: Hours ____ Minutes ____
 (reading articles and completing the learning assessment and evaluation)

THE MONOGRAPH AND TEST EXPIRE APRIL 25, 2009.

PRINT OR TYPE

Last Name		First Name	Degree
Mailing Address			
City		State	Zip Code
Date of Birth (used for tracking credits ONLY)			
Phone Number	FAX Number	E-mail	

EVALUATION (must be completed for your CME Quiz to be scored)
 Using the scale below, circle the number that corresponds with your opinion for each item.

1 = poor; 2 = fair; 3 = satisfactory; 4 = good; 5 = excellent

- Rate the clinical usefulness of the monograph to your daily practice. 1 2 3 4 5
- Rate the effectiveness of the teaching/learning methods. 1 2 3 4 5
- Did the material in this educational activity meet the learning objectives? 1 2 3 4 5
- Please rate the degree to which the content presented in the activity was free from commercial bias.

No bias				Significant bias
5	4	3	2	1

Comments regarding bias: _____

- List one new thing you learned that can be applied to your practice: _____
- Are there any other topics you would like to have seen addressed in this monograph? _____

CME ACTIVITY REQUEST

7. Yes, I would like the opportunity to earn CME credits through activities sponsored by Vindico Medical Education.

CME FORMAT PREFERENCE

On a scale of 1 to 5, please rank each of the following formats for which CME may be provided:

- 1 = not useful; 2 = somewhat useful; 3 = useful; 4 = very useful; 5 = extremely useful**
- Newsletter 1 2 3 4 5
 - Videotape 1 2 3 4 5
 - Monograph/Journal Supplement 1 2 3 4 5
 - Symposium/Conference 1 2 3 4 5
 - Web-based/CD-ROM 1 2 3 4 5

- According to CISNET models examining the relationship between screening and adjuvant treatment and breast cancer incidence and mortality, the combination of screening and treatment has accounted for an estimated _____ drop in mortality in the period from 1975 to 2000.
 - 10% to 22%
 - 25% to 38%
 - 42% to 52%
 - 67% to 81%
 - None of the above
- An EBCTCG meta-analysis of 195 randomized trials of adjuvant therapies conducted since 1995 found that:
 - Single-agent chemotherapy significantly reduced rates of recurrence and mortality
 - Polychemotherapy had a significantly greater favorable effect on recurrence and mortality than single-agent regimens
 - Polychemotherapy significantly reduced rates of recurrence and mortality
 - Anthracycline-based regimens offered a significant advantage over CMF (cyclophosphamide, methotrexate, fluorouracil) as adjuvant therapy
 - All of the above
- The relationship between HER2 overexpression in breast cancer and responsiveness to anthracycline may be related to _____.
 - VEGF α
 - VEGF β
 - BCR-ABL
 - TOP2A
- In an analysis of the prognostic and predictive value of the Oncotype DX 21-gene RS assay in the SWOG 8814 trial, the RS assay _____.
 - Demonstrated significant differences in survival outcomes among high-, intermediate-, and low-risk groups in the tamoxifen arm
 - May be useful in determining patients with node-positive, postmenopausal disease who will benefit from adjuvant anthracycline therapy added to hormonal therapy
 - Was prognostic for disease-free survival and overall survival in the tamoxifen arm
 - All of the above
 - None of the above
- The current standard option for adjuvant endocrine therapy in premenopausal women is tamoxifen continued for 10 years.
 - True
 - False
- Early results from the ATLAS trial suggest that:
 - The therapeutic benefit of tamoxifen therapy may be limited to 5 years
 - Agree with the findings from the NSABP 14 study
 - Continuing tamoxifen therapy for an additional 5 years confers about a 12% reduction in risk of recurrence compared with tamoxifen discontinued after 5 years
 - None of the above
- Findings from the ATAC trial demonstrated that anastrozole was associated with _____ compared with tamoxifen.
 - Lower risk of recurrence and greater risk of fracture, though fracture risk normalizes after completion of therapy
 - Significantly higher risk for recurrences
 - No advantages in OS, DSF, and TTR
 - None of the above

OFFICE USE ONLY	
Enduring material: Internet	
April 25, 2008	J304